Abstract
The progress in genome-scale approaches to human diseases will soon require to understand the function of a large number of genes as potentially interesting therapeutic targets. The determination of their biological role needs to be accelerated in order to select valid therapeutic targets and streamline the drug discovery process. The sequencing of the human genome, as well as a number of model organisms, provides a strong framework to achieve this goal. Several methods among which gene expression profiling and protein interaction mapping are being used on a large-scale basis and constitute useful entry points to identify pathways involved in disease mechanisms. The resulting information is however limited. Other methods rely on the genetic manipulation of well-characterized and simple model organisms (SMOs) to reconstruct human disease-associated pathways and pinpoint biologically-valid therapeutic targets on the basis of function-based datasets generated in vivo. SMOs are strongly complementary to well-established complex mammalian models, and multiple ways exist to integrate SMOs into the early stage of the drug discovery process. In this review, we attempt to highlight some of the general criteria and essential methodological components associated with the use of SMO technologies for rapid functional genomics. Examples are provided to illustrate the utility of C. elegans and Drososphila for the validation of targets for central nervous system drugs.
Keywords: Therapeutic Targets, Simple model organisms SMOs, ESTs, CDNAs, Protein, EST expression Profiles, Biallelic Single uncleotide markers, DNA array, Proteomics, Target Validation
Current Genomics
Title: Defining Therapeutic Targets in Simple Model Organisms
Volume: 1 Issue: 2
Author(s): F. Thomas and C. Neri
Affiliation:
Keywords: Therapeutic Targets, Simple model organisms SMOs, ESTs, CDNAs, Protein, EST expression Profiles, Biallelic Single uncleotide markers, DNA array, Proteomics, Target Validation
Abstract: The progress in genome-scale approaches to human diseases will soon require to understand the function of a large number of genes as potentially interesting therapeutic targets. The determination of their biological role needs to be accelerated in order to select valid therapeutic targets and streamline the drug discovery process. The sequencing of the human genome, as well as a number of model organisms, provides a strong framework to achieve this goal. Several methods among which gene expression profiling and protein interaction mapping are being used on a large-scale basis and constitute useful entry points to identify pathways involved in disease mechanisms. The resulting information is however limited. Other methods rely on the genetic manipulation of well-characterized and simple model organisms (SMOs) to reconstruct human disease-associated pathways and pinpoint biologically-valid therapeutic targets on the basis of function-based datasets generated in vivo. SMOs are strongly complementary to well-established complex mammalian models, and multiple ways exist to integrate SMOs into the early stage of the drug discovery process. In this review, we attempt to highlight some of the general criteria and essential methodological components associated with the use of SMO technologies for rapid functional genomics. Examples are provided to illustrate the utility of C. elegans and Drososphila for the validation of targets for central nervous system drugs.
Export Options
About this article
Cite this article as:
Thomas F. and Neri C., Defining Therapeutic Targets in Simple Model Organisms, Current Genomics 2000; 1 (2) . https://dx.doi.org/10.2174/1389202003351544
DOI https://dx.doi.org/10.2174/1389202003351544 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Mitochondrial Impairment in Alzheimer´s Disease Neurodegeneration: The Tau Connection
Current Neuropharmacology Multiple Sclerosis: Risk Factors and their Interactions
CNS & Neurological Disorders - Drug Targets Regulation of Inflammation: A Review of Recent Advances in Anti- Inflammatory Strategies
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile
Current Drug Safety Aquaporin Biology and Nervous System
Current Neuropharmacology Placebos Used in Clinical Trials for Chinese Herbal Medicine
Recent Patents on Inflammation & Allergy Drug Discovery Fibrinolysis: The Key to New Pathogenetic Mechanisms
Current Medicinal Chemistry Neurobiological Evidence for the Primacy of Mania Hypothesis
Current Neuropharmacology The Role of Adenosine in Alzheimers Disease
Current Neuropharmacology Effect of Temperature and pH on the Secondary Structure and Denaturation Process of Jumbo Squid Hepatopancreas Cathepsin D.
Protein & Peptide Letters Can We Detect Psychotic-like Experiences in the General Population?
Current Pharmaceutical Design Transcriptomics
Current Drug Metabolism Erratum:
Current Neuropharmacology Selective Dopamine D3 Receptor Antagonists: A Review 2001-2005
Recent Patents on CNS Drug Discovery (Discontinued) Significance of CD34 Negative Hematopoietic Stem Cells and CD34 Positive Mesenchymal Stem Cells – A Valuable Dimension to the Current Understanding
Current Stem Cell Research & Therapy Therapeutic Antibodies for Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets Biologicals Dramatic Advances in the Treatment of Psoriasis
Current Pharmaceutical Design Recent Progress in Biological Activities and Synthetic Methodologies of Pyrroloquinoxalines
Mini-Reviews in Medicinal Chemistry Synthesis, Molecular Docking and In Vitro Antimicrobial Studies of Novel Pyrazole Analogues of Curcumin
Letters in Drug Design & Discovery Investigation of Prevalence and Complications of Female Genital Circumcision: A Systematic and Meta-analytic Review Study
Current Pediatric Reviews